Management of gastrointestinal involvement in scleroderma
V Nagaraja, ZH McMahan, T Getzug… - Current treatment options …, 2015 - Springer
Opinion statement Gastrointestinal tract (GIT) is commonly involved in patients with systemic
sclerosis (SSc). The GI involvement is quite heterogeneous varying from asymptomatic …
sclerosis (SSc). The GI involvement is quite heterogeneous varying from asymptomatic …
Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management
ZH McMahan, S Kulkarni, J Chen, JZ Chen… - Nature Reviews …, 2023 - nature.com
Nearly all patients with systemic sclerosis (SSc) are negatively affected by dysfunction in the
gastrointestinal tract, and the severity of gastrointestinal disease in SSc correlates with high …
gastrointestinal tract, and the severity of gastrointestinal disease in SSc correlates with high …
Gastrointestinal involvement in systemic sclerosis: an update
ZH McMahan - Current opinion in rheumatology, 2019 - journals.lww.com
SSc gastrointestinal disease is heterogeneous in its clinical presentation, which presents a
challenge in diagnosis and management. In the past year, several studies have evaluated …
challenge in diagnosis and management. In the past year, several studies have evaluated …
Symptoms of autonomic dysfunction in systemic sclerosis assessed by the COMPASS-31 questionnaire
…, JW Russell, LK Hummers, ZH McMahan - The Journal of …, 2018 - jrheum.org
Objective. Autonomic dysfunction is a known complication of systemic sclerosis (SSc) that
can affect vascular tone, gastrointestinal (GI) motility, heart rate, and blood pressure control. …
can affect vascular tone, gastrointestinal (GI) motility, heart rate, and blood pressure control. …
[HTML][HTML] Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management
ZH McMahan, FM Wigley - International journal of clinical …, 2010 - ncbi.nlm.nih.gov
Digital ischemia is a painful and often disfiguring event. Such an ischemic event often leads
to tissue loss and can significantly affect the patient’s quality of life. Digital ischemia can be …
to tissue loss and can significantly affect the patient’s quality of life. Digital ischemia can be …
Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases
ZH McMahan, CO Bingham III - Arthritis research & therapy, 2014 - Springer
Vaccinations are administered to patients to induce a protective immune response, resulting
in immunological memory. Preventing infection through the use of vaccines is particularly …
in immunological memory. Preventing infection through the use of vaccines is particularly …
Anti–RNPC‐3 (U11/U12) antibodies in systemic sclerosis in patients with moderate‐to‐severe gastrointestinal dysmotility
ZH McMahan, RT Domsic, L Zhu… - Arthritis care & …, 2019 - Wiley Online Library
… McMahan's work was supported by a Jerome L. Greene Scholar award, the Rheumatology
Research Foundation, a Johns Hopkins Clinician Scientist Career Development award, and …
Research Foundation, a Johns Hopkins Clinician Scientist Career Development award, and …
Determining the risk factors and clinical features associated with severe gastrointestinal dysmotility in systemic sclerosis
ZH McMahan, JJ Paik, FM Wigley… - Arthritis Care & …, 2018 - Wiley Online Library
Objective A subset of patients with systemic sclerosis ( SS c) develop severe gastrointestinal
( GI ) dysmotility. We sought to determine predictors of severe SS c GI dysmotility and to …
( GI ) dysmotility. We sought to determine predictors of severe SS c GI dysmotility and to …
An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis
ZH McMahan, ER Volkmann - Expert opinion on pharmacotherapy, 2020 - Taylor & Francis
Introduction Systemic sclerosis (SSc) is a multi-dimensional connective tissue disease of
unknown etiology. Given the immense clinical complexity of SSc, the treatment of this condition …
unknown etiology. Given the immense clinical complexity of SSc, the treatment of this condition …
Risk of Malnutrition in Patients With Systemic Sclerosis‐Associated Interstitial Lung Disease Treated With Nintedanib in the Randomized, Placebo‐Controlled …
ER Volkmann, ZH McMahan, V Smith… - Arthritis Care & …, 2023 - Wiley Online Library
Objective To assess adverse events (AEs) in relation to baseline body mass index (BMI)
and the risk of malnutrition in patients with systemic sclerosis–associated interstitial lung …
and the risk of malnutrition in patients with systemic sclerosis–associated interstitial lung …